- SIG +19% on Q2 result.
- LTRX +17% on Q4 result.
- MIK +14% on Q2 result.
- ANF +14% on Q2 result.
- GES +13% on Q2 result.
- TLYS +11% on Q2 result.
- DLTR +10% on Q2 result.
- TTNP +10% as FDA clears Titan Pharmaceutical's IND application for Ropinirole Implant.
- BURL +8% on Q2 result.
- WSM +8% on Q2 result.
- SHLD +7% on Q2 result.